Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that ER negative, HER2-negative, PD-L1 >= 1%, and PR negative status confers therapeutic sensitivity to Atezolizumab, Nab-paclitaxel in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab in combination with nab-paclitaxel for reimbursement as a treatment option for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors have PD-L1 expression >= 1% and who have not received prior chemotherapy for metastatic disease.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression >= 1% and who have not received prior chemotherapy for metastatic disease
Citation
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2024-01-16 | Van Allen lab | Adding HSE approvals for reimbursement to database |
| 2022-03-01 | Health Service Executive | Indication approved for reimbursement. |